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Abstract
This paper analyses promissory discourse for genome editing and human health in the UK, attending to the articulation of public goods and
their beneficiary publics. Focusing on promissory reasoning about an emerging technology field as anticipatory and ethical considerations as
integral to such debates, the notion of ethical regime as a mode of governance is applied to the concept of promissory regime. By analyzing key
documents and interviews with opinion leaders—thus focusing on the discursive dimension—an enabling promissory ethical regime for genome
editing and its contestation are identified. This regime posits scientific knowledge production now, and improved treatment or prevention of
hereditary diseases later, as key goods of genome editing for human health and as a sociotechnical project worthy of support. Specific publics
are created as beneficiaries. These publics and goods play out as ethical rationales for the promissory governance of the emerging field of
human genome editing.
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1. The promise of an update
Genome editing refers to the rapidly emerging ability
to make—in a qualitatively better way than previously
possible—targeted and controlled changes in the DNA and
RNA of humans and other organisms1 Scientific research
in genome editing has progressed considerably over the last
two decades, and, especially, since the realization of the
CRISPR/Cas9 technique for human genome editing in 2012,2
the promise of precise, versatile, and affordable genetic
changes in somatic and germline cells has entered the realm
of feasibility. Advocates of genome editing refer to its capac-
ity for directed genomic change and to the broad continuum
of potential applications that mark it out as enabling. Others
emphasize the potentially disruptive3 nature of genome edit-
ing and call for a broad societal consensus on its necessity and
appropriate use before further development of the technology.
Information on genome editing produced by a variety of
sources addresses interested publics without assuming they
have significant scientific knowledge, offering an introduc-
tion to genome editing that emphasizes the technology field’s
enabling nature. The UK debate is characterized by a plethora
of promissory references to the potential(s) and future(s) of the
capacity to ‘edit’ and ‘engineer’4 the human genome. These
metaphors evoke notions of skill, craft, and most crucially of
improving on or ‘updating’5 a body of work. While health and
ill health are clearly portrayed as key concerns to the intended
audiences, the notion of the update is particularly encompass-
ing and promissory. Like ‘edit’, it articulates an imaginary of
correction or restoration rather than disruption of the human
genome. A further key message is inevitability, coupled with
an affirmative mode emphasizing both the potential benefits
and society’s capacity to regulate the field so that any negative
impacts can be avoided.
This paper addresses the developing promissory regimes of
genome editing in the UK since 2015 during a period when a
series of high-profile statements were published by British sci-
ence institutions. Using a sample of key ethical documents and
opinion leaders’ views, we examine how influential opinion-
maker voices in the public discussion identify particular goods
that genome editing will provide and also which publics are
imagined as the beneficiaries of these goods. This illuminates
which ethical concerns are articulated in the sociotechnical
imaginaries of genome editing and how promissory regimes
are structured by these ethical concerns.
2. Sociotechnical imaginaries, ethics, and
promissory regimes
Sociotechnical imaginaries are collectively produced visions
of what constitutes a good society.6 They contribute to
the structuring of anticipatory discourse7 that aims to inte-
grate foresight and engagement about emerging technologies
into programmes of support and development.8 The abil-
ity to develop and act upon such imaginaries by negotiating
plausible visions9 and actionable programmes depends on
interactions between sociotechnical networks,10 eventually
producing distinct ethical regimes that both reflect and shape
the sociotechnical imaginary’s values and norms about desired
© The Author(s) 2021. Published by Oxford University Press.
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futures.11 The term ethical regime describes the arrange-
ment of systems and frameworks, values and norms that
govern research, and potential clinical interventions12; eth-
ical regimes may change over time, and so require con-
stant negotiation work. Ethical discourses around as-yet
un(der)developed technologies are promissory, since they are
an anticipatory as well as regulatory element of sociotechni-
cal imaginaries: they reassure publics that future actions will
be ethical and serve the ideal of a good society.13 Active work
is required to develop a durable infrastructure in which such
imaginaries are realised and which can assure audiences that
the processes of knowledge production and use, and their gov-
ernance mechanisms, are legitimate and ethical and that the
emerging materials and knowledges are subject to an ethical
regime that produces public goods for appropriate, deserving
publics. Promissory ethical regimes are thus emerging delib-
erative governance frameworks, drawing on expectations,
visions, and statements of intent in attempting to material-
ize practices, structures, and relationships toward a desirable
future based on shared values.
3. Publics and public goods
The design of sociotechnical projects involves the promissory
articulation of public goods that the technology may gen-
erate and of the publics who might benefit. In this paper,
publics and public goods are taken as discursive elements14
in the development of promissory regimes of genome editing.
There has been significant scholarly discussion of different
publics and their perceptions of science,15,16,17 especially in
relation to the communication and governance of risk18,19
and the contrasting scientific deficiency versus political com-
petence of the ‘public in general’.20 Mike Michael describes
public engagement as not merely expressive (i.e. enabling peo-
ple to voice their citizenly concerns) but also constitutive:
participants in variously choreographed forms of engage-
ment are ‘performing’ and eventually ‘make’ a public. Public
engagement often entails relating an undifferentiated ‘public
in general’ to an equally undifferentiated ‘science in gen-
eral’. Michael’s concept of ‘publics-in-particular’21 describes
groups with an active stake in a given technological issue that
necessarily emerge alongside the development of the technol-
ogy. Publics-in-particular for any technology develop through
complex, dynamic and unending interactions between polit-
ical, economic, clinical, moral and other influences. Part of
this process involves people identifying themselves within a
public-in-particular, for example as candidates for a future
genome editing trial.22 In our study, we decided to focus on
the role of ‘expert’23 stakeholder perspectives in ‘creating the
framework of ethical discourse’ by assigning public goods
and, in tandem, publics.24
The discourse of public goods is closely related. Public
goods are articulated to resemble properties and services made
available to members of a community and the practicalities of
who could or should benefit from what opens up the rela-
tional, dynamic nature of publics-in-particular. The public
connotation does not necessarily derive from the provision
of these goods via a public body. Michel Callon has argued
that any difference between public and private goods is only
arrived at through negotiations about rationales of, and access
to, the said goods.25 Difference derives from the expecta-
tion that no such benefits will be unreasonably restricted to
certain groups and that they are not subject to zero-sum
considerations.26 More specifically, goods are discursively
related to specific publics, that is, constituencies who meet the
articulator’s specific criteria. It is becoming axiomatic that the
negotiation of public goods should also be subject to public
forms of deliberation and governance, especially in life science
innovations, as was the case for mitochondrial replacement,
and increasingly so for genome editing. In our analysis, we
apply the concept of public goods to the claims and ideas
expressed in the data sources we analysed.
4. The genome editing discussion in the UK
The genome editing discussion in the UK is distinctive. It plays
out as a deliberative governance approach to health-related
research that positions publics as partners in dialogue.27 Since
the late 1990s, the role of patients and publics in UK health
research and care has shifted from that of medical subjects
to one of essential partners, resulting in a present-day health
policy framework that arguably sees publics as assets to the
political economy of the UK’s national biomedical project.28
Within this context, growing political and commercial
ambition for genomic science is evidenced in a series of devel-
opments, including the establishment of the UK Biobank as
‘a national and international health resource with unparal-
leled research opportunities’29 and the public announcement
in late 2012 by then Prime Minister David Cameron of a
project to sequence 100,000 genomes from National Health
Service (NHS) patients with cancer or a rare disease by 2017.
The Department of Health established a company, Genomics
England, to manage the 100,000 Genomes Project and ‘to
bring the predicted benefits of genomics to NHS patients’ as
well as to advance research.30 In October 2018, the NHS
then announced a new genomic medicine service, including
the expanded goal of sequencing 5 million genomes over the
next 5 years.31 The political importance of genomics to the
positioning of the UK in the global scientific and healthcare
landscape shapes the policy, professional, and public discus-
sion of genomic medicine’s ethics and regulation. Genome
editing can be seen as the latest and so far most high-profile
iteration of that.
Genome editing is not one technology but a growing field
of technologies and applications, and this diversity needs to
be taken into account in any ethical, regulatory, and public
debates. Distinctive ethical and practical challenges are likely
to emerge for individual technologies, and responding to them
has the potential to shift social and moral norms. Since 2015,
concerted efforts have been made to identify areas that require
urgent ethical and legal deliberation, most pressingly clinical
applications that would entail germline (heritable) editing.
The UK has seen significant policy discourse around
genome editing, involving some of the country’s key players in
science governance. In September 2015, a joint statement32 by
the Academy of Medical Sciences, the Association of Medical
Research Charities, Cancer Research UK, the Biotechnology
and Biological Sciences Research Council (BBSRC), the Medi-
cal Research Council (MRC), the Progress Educational Trust,
the Wellcome Trust, and the Wellcome Trust Sanger Institute
strongly advocated the further development of genome edit-
ing research. Also, in 2015, the Hinxton Group33 released
a statement in favour of further scientific and technologi-
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ethical evaluation of the technology field is needed before
clinical applications should be considered. In February 2016,
the first UK license for the use of the CRISPR technique in
a human embryo was granted, generating significant media
coverage.34,35,36 Three months later, Sciencewise37 and the
Nuffield Council on Bioethics38 reported on the need for pub-
lic engagement in discussions of genome editing. In September
2016, the Nuffield Council on Bioethics published an early
ethical review, defining genome editing and its key applica-
tions while making the case for further ethical deliberation.
This report was referenced in a POSTnote39 on genome edit-
ing by the Parliamentary Office of Science and Technology
and also in a position paper by the Church of England.40 In
November 2016, the Genetic Alliance UK, an umbrella body
for over 180 patient organizations, joined the public debate
by urging more engagement with patients, offering data on
patients’ perceptions of and key concerns about genome edit-
ing.41 The Chief Medical Officer’s annual report for 2016
made several references to genome editing in its discussion of
genomic service provision in the NHS.42 In 2017, the House
of Commons Science and Technology Committee released
a brief scoping report to prepare for further deliberation43
and, in September of the same year, the Genetic Alliance UK
and the Progress Educational Trust, supported by the Well-
come Trust, released their report on the Basic Understanding
of Genome Editing, with key recommendations on content,
mode, language, and visualizations in public communication
about the field.44 Within a couple of years, the subject of
genome editing had well and truly arrived on the UK’s science
policy agenda.
Within the academic and research-focused science policy
communities, many senior scientists currently propose a lin-
ear narrative where the first step must be to establish the safety
and efficacy of the technologies, next consider what to use
them for, and only then enter into a debate about whether
that use is socially acceptable. Some of the professional and
policy statements mentioned above, however, suggest that
these aspects should be considered in parallel. There are crit-
ical voices in the UK setting, challenging the scientific focus
on the primacy of feasibility, safety, and efficacy and calling
instead for a prior and broader societal discussion of the social
norms and human values that underpin the supposed need
for technologies such as genome editing. These voices share
some concerns about the commodification of humans and the
potential for using germline gene editing technology to disrupt
social covenants on norms of parenthood and care, reproduc-
tive freedoms, race and ethnicity, disability and diversity, and
so on. While these critiques are levelled within the UK regu-
latory context that permits genome editing research on early
embryos but prohibits clinical application, they are neverthe-
less informed by the very different regulatory situations in
other countries, ranging from very restrictive to moderately
permissive.
5. Methodology
This was a scoping study combining (1) documentary exami-
nation of four key statements and reports on human genome
editing published between 2015 and 2017 and (2) thematic
content analysis of five semi-structured face-to-face interviews
with key informants from genomic science held betweenOcto-
ber 2017 and February 2018. The selected documents were
authored by key decision-makers representing a variety of
major stakeholder groups in genome editing. They are easily
available to a wide readership and have become cornerstones
of the UK policy debate.45
To complement the documentary analysis, in-depth inter-
views were held with five selected key informants. These
respondents were chosen because they had been, or were rec-
ommended by, co-authors or reviewers of a major report on
genome editing at the time of the research. These individuals
are senior figures within biomedical science, ethics, research,
and public policy and are well placed to provide insights into
the thinking of the main agencies shaping the public discourse
of goods and beneficiaries of genome editing in the UK. The
interview informants work in professional areas with specific
but distinct interests and roles in genome editing. They were:
two academic scientists working on genome editing in ani-
mal models; one public engagement specialist from a major
national research funding organization that invests heavily
in genome editing; one university-based ethicist with exten-
sive experience in ethical governance in genome research; and
one social analyst involved in public deliberation and pol-
icy discourse about genome editing. The interviews provide
some detail on how genome editing resembles or differs from
related technologies in terms of the public goods and publics
produced and, as such, offer contextualizing information to
the reports on genome editing by placing the debate alongside
previous and ongoing biotechnological discussions.
Each interview was held at a place and time of the inter-
viewees’ choice, lasted approximately 1 hour, and was audio
recorded and transcribed by one of the authors (AUTHOR1).
Both authors then took part in the thematic content analy-
sis. Once themes were identified, they were cross-referenced
across all interviews to get a qualitative sense of common-
ality and strength. Given the small number of interviews
and subjective nature of responses, we were primarily inter-
ested in characterizing shared ideas about beneficiary publics
and public goods rather than differences between professional
roles.
6. Key reports and statements
This section presents an analysis of four widely publicized
and discussed statements and reports on human genome edit-
ing from the UK, focusing on how public goods and their
associated publics are articulated. The documents include the
Joint Statement of UK Research Funders (2015), the Hinxton
Group Statement (2015), the Nuffield Council on Bioethics’
‘Genome editing: an ethical review’ (2016), and the report by
the Genetic Alliance UK on ‘Genome editing technologies: the
patient perspective’ (2016).
The two 2015 statements can be firmly located in an
environment of alert responsiveness to what the Joint State-
ment calls ‘rapid technological developments in this area’
with CRISPR/Cas9, and a marked increase in the number
of scientific publications on genome editing since the jour-
nal Nature Methods crowned ‘gene editing’ the method of
the year 2011.46 These statements and subsequent reports
emerged in the context of the realization that the velocity
of developments would increase, as would interest by new
players: the relative ease of use of CRISPR/Cas9 expands the
groups that could be involved in editing the genome. Simul-
taneously, economic and innovation policy interests have
emerged, prompting some direct and less direct responses in
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6.1 The Joint Statement of UK Research Funders
2015
This brief but often-referenced statement focuses on the
‘potential to improve health’ and ‘therapeutic effect’ as long-
term gains from editing the genome in human cells. In doing
so, it reflects the way that the UK’s professional and public
discussion of genomic science is based firmly on the thera-
peutic imperative. Still, the signatories emphasize that clinical
applications require much more basic research,47 arguing that
‘research using genome editing tools holds the potential to sig-
nificantly progress our understanding of many key processes
in biology, health and disease’. The statement reflects on the
field of genome editing as organically emerging, suggesting
a history of a so far safe development of the technological
foundations of genome editing. The statement indirectly calls
upon decision-makers to build upon this history by ‘clearly
demarcating’ frameworks for research and for clinical use
and ensuring that the research community retains the lead in
the field; against whom is not made clear but is likely to be
players in applications, for example, commercial health tech-
nology and service providers, as well as applied researchers in
countries with less stringent research governance.48
The statement therefore links value primarily with
research-based knowledge production but contextualizes it
in terms of safety frameworks and knowledge that enables
future clinical application for somatic cell editing. The state-
ment keeps open the possibility that research may also lead
to germline applications. For the signatories of this docu-
ment, the key constituency remains the research community
affected by decisions about genome editing, and they indi-
rectly enroll decision-makers in science/research/innovation
and related policy-makers in developing an ethical framework
for further work.
6.2 The Hinxton Group Statement 2015
The Hinxton Group statement places genome editing within a
decades-long history of genetic modification in animals and of
ethical debate about human genome modification. The Group
points out that, while more recent technological developments
do not change the ethical issues, the scientific environment
overall (genetic/genomic knowledge and capacities, decrease
in costs, and globalization) has significantly shifted toward
enabling the unregulated use of new techniques. The Group
aims therefore to inform debate and decision-makers who are
seen as an active audience and less as an affected public.
The Statement focuses on assisted reproduction and
germline editing in embryos, identifying two broad affected
publics: prospective parents and communities in which herita-
ble conditions are prevalent and where clinical intervention in
reproduction may be relevant. Nevertheless, the authors only
tentatively approach clinical use, suggesting instead that con-
siderable further basic research is needed, re-framing the cur-
rent value of genome editing not as direct health improvement
but as the expansion of knowledge:
Genome editing has tremendous value as a tool to address
fundamental questions of human and non-human animal
biology and their similarities and differences. […] it is
our conviction that concerns about human genome editing
for clinical reproductive purposes should not halt or ham-
per application to scientifically defensible basic research.
(pp. 2–3)
The focus on research extends to any kind of basic research
that may generate useful knowledge for clinical applications.
The Group remains agnostic about the future trajectory for
genome editing, framing it as dependent on research as well
as on deliberation and good governance, advocating further
support and development of the technology until ‘all safety,
efficacy and governance needs are met’ (p. 4). The statement
makes a clear distinction between research and application
and prioritizes further support for the former like the authors
of the Joint Statement of UK Research Funders.
6.3 The Nuffield Council on Bioethics ethical review
2016
The review provides a detailed introduction to scientific and
medical aspects of genome editing, scoping potential applica-
tion fields, and identifying key ethical questions. Its overall
assessment finds that ‘while the scientific merits are overt, the
practical and ethical significance of these recent developments
is far harder to discern’ (p. 1). It describes an environment
of scientific push rather than societal pull based on ‘demand
from researchers and high-profile advocacy by the developers
and early adopters, and enabled by the conditions and cul-
ture of research in the biological sciences’ (p. 14) but also a
demand by those actors in the health research sector whowant
access to early stage technologies, such as patients or relevant
charities, or to develop marketable therapies, such as com-
mercial developers (p. 44). The potential public is described
broadly as benefiting from research into ‘understanding of
health and disease’ (p. 35) and the further development of
editing techniques. A second broad area of potential benefit
is clinical therapy, for example, for cancer: ‘Cell-based thera-
pies have potentially significant advantages over conventional
treatment options in terms of both effectiveness and legacy,
since the modified immune cells selectively and continuously
attack the cancer cells without damaging unaffected tissues’
(p. 41). Other potential areas mentioned include infectious
diseases such as hepatitis and AIDS, rare diseases such as
muscular dystrophy, and xenotransplantation.
The review also covers enhancement, ranging from preven-
tative gene therapy aiming to ‘reduce the risk of conditions for
which genetic variations are known risk factors, or to pre-
vent disease, for example by enhancing immunity’ (p. 50),
to reproductive interventions that may be understood as the
“‘consumerisation” of human biology’ (p. 52). Genome edit-
ing in human reproduction is identified as one of the areas
most urgently in need of ethical deliberation (p. 115).
The discussion indicates how the Nuffield Council on
Bioethics identifies some of the key publics involved in genome
editing. These range from clinicians, to specific groups of
patients, and on to the future consumers of genome edit-
ing. The report also refers directly to ‘human subjects’ in
research and potential trials of a ‘therapeutic product’ (p. 44),
to charities, and to commercial interest in genome editing.
6.4 The Genetic Alliance UK (2016) report
The Genetic Alliance UK is an umbrella association of patient
organizations. Their online survey of attitudes to genome edit-
ing received over 200 responses, primarily from individuals
with genetic conditions, family members and carers. The sur-
vey covered five areas: awareness of and interest in genome
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picture (risk versus benefit). The report identified three key
themes for the future of genome editing: research, treatment,
and prevention.
The report notes that respondents show significant sup-
port for genome editing for research and medical treatment
or prevention. Any use should be based on informed con-
sent, and treatment should be managed by expert clinicians.
Respondents emphasized both need and equity for access to
such treatment. Enhancement in the absence of medical need
was reported as having significantly less support in the sur-
vey responses. The notion of the ‘designer baby’ appears
(pp. 22–23), tempered by the authors’ assessment that selec-
tive enhancements will not be possible for some time yet.
While respondents showed concern about commercial
providers of genome editing services, many suggested that
both the NHS and companies should be able to offer edit-
ing services in the UK, the EU, and globally, indicating an
appetite for consumer choice in a market offering diverse
techniques and services. The report also suggests that respon-
dents prefer regulation based on existing modes of deliber-
ative engagement, including a role for patients in a multi-
stakeholder approach involving government, researcher, and
clinicians. Respondents also expressed interest in an interna-
tional approach to regulation, which aligns with their desire
to have access to global service providers.
The Genetic Alliance survey asked respondents to indicate
the balance of benefit and risk they thought genome editing
offered: 136 out of 153 responses indicated a clear weighting
toward benefits.
6.5 Summary of the reports
The analysis of these four reports suggests that, overall, two
main public goods dominate the genome editing discussion in
the UK: (1) the advancement of genetic and genomic knowl-
edge using genome editing techniques and (2) the improve-
ment of quality of life via progress in healthcare. The minimal
consensus across these four documents is that the field is still
firmly in the realm of research and not yet a candidate for
clinical application. At the same time, much of the public dis-
course (e.g. as seen in the Genetic Alliance’s survey results) is
about ensuring the safe future application of genome editing.
Notably, none of these published statements (nor, as we shall
see, the interview data) seriously question whether resources
should go toward genome editing in the first place.49 The
documents also suggest that basic research and ethical deliber-
ation need to be undertaken simultaneously, ideally involving
a wide range of different stakeholders.
In line with these public goods, the sociotechnical imagi-
nary of these documents configures the key beneficiary publics
as the research community and individuals/families for whom
genome editing might be therapeutic. The documents show
more variation in terms of imagined publics than in pub-
lic goods. For example, although the Joint Statement of UK
Research Funders targets the research community, it also
articulates the need for timely engagement with a range of
potential public audiences, including ‘biomedical and social
scientists, ethicists, healthcare professionals, research funders,
regulators, affected patients and their families, and the wider
public’. By comparison, the Genetic Alliance focuses entirely
on ‘the profound unmet need’ of individuals with specific
genetic conditions (p. 34) and their hope that genome editing
will lead to new treatment and/or prevention.
7. Interview data
Like the documents, in the interviews, the advancement of
knowledge is given as a central motivating good driving the
need for progress in the field. Advancement toward develop-
ing procedures and techniques for genome editing comes prior
to developing clinical contexts. The following quote illustrates
several of these points:
[…] my feeling is it would have to be safer because people
are going to be so jittery about the technology that they’re
going to expect a very high standard of efficacy.… And not
just because of what’s already available, in the minds of
some people anyway, through PGD, but because of some
of these other… These genes, Jesse Gelsinger,50 you know,
where things have gone horribly wrong. They’re going to
want to make sure as much as it’s possible to make sure—
and it never is completely—as much as is possible, that
there are not going to be any bad outcomes which would
of course potentially cause a reaction against the whole
enabling approach. Enabling in the minds of some peo-
ple. So people like me by the way, I think it’s a discussion
of how to handle it, really. It’s not for me a question of
whether it should be done; it’s about making sure it’s done
right. (Scientist 1)
Several informants put forward the argument that scien-
tific knowledge about the human genome and genome edit-
ing techniques is a public good in itself. Genome editing
is described as holding the ‘potential to be revolutionary in
research—to help inform our understanding of human biol-
ogy’,51 and the technology is cast as part of a virtuous cycle
in which ‘scientific knowledge is a major driver of it, and
[so is] anything that feeds into scientific knowledge’ (Inter-
view with scientist 2). Other proponents of genome editing in
research, such as the Hinxton Group, have also argued that
emerging knowledge is a valuable enough public good to over-
ride other ethical or precautionary considerations: ‘concerns
about human genome editing for clinical reproductive pur-
poses should not halt or hamper application to scientifically
defensible basic research’.52
Moreover, the good of genomic knowledge is nearly always
contextualized in terms of future applications in clinical
contexts—as the Academy of Medical Sciences report noted,
‘a powerful technology that has the potential to improve
health’.53 This reinforces the second major public good found
in these interviews, namely improved quality of life and health
at the collective and the individual levels.
It can alleviate or prevent heritable disease, if we’re talking
about heritable genome editing; and it can prevent dis-
ease that’s genetic if we’re talking about somatic genome
editing. (Scientist 1)
The interview responses indicate that the capacity for
genome editing to deliver public goods is highly dependent
on scientific variables, such as achieving maximum preci-
sion in targeting alleles; avoiding somatic changes that affect
the germline; limiting interventions to desired effects (e.g.
avoiding off-target effects or mosaicism); keeping open future
manipulation (e.g. by clearly marking edited loci); and under-
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Interview respondents draw the scope of the technology
field to include somatic and germline editing and even more
promissory applications as indicated by the scientist who
describes genome editing as part of ‘the whole enabling
approach’. Emphasis is placed on ‘necessary repairs within
the patient’s body’54 along a continuum between treatment—
for example, using somatic cell editing—and enhancement of
traits using germline editing, but with ethical ‘boundarymark-
ers’ along the continuum, where prevention of ill health is
more likely to be considered ethical than selective enhance-
ment of traits not directly related to health. This reflects the
longstanding biomedical consensus that genome editing may
be indicated for conditions affecting relatively small numbers
of people and concentrating on possible early ‘wins’ in assisted
reproductive technologies (ARTs). Nevertheless, other areas
were also proposed. One trajectory for research is to further
develop the understanding of genomic mechanisms, explor-
ing ever more complex areas and moving future health-related
treatment options beyond rare diseases, for example, inter-
ventions to enhance resilience against trauma and sepsis, and
so becoming more of a general public good. The emergence
of interventions like these, some interview respondents argue,
changes ethical and regulatory deliberation significantly:
Let’s say you could gene edit people so that they would
heal more quickly from bone fractures or something. […]
Some people are more likely to develop sepsis than others,
some people are more likely to respond well to treatment
in intensive care. […] You’d think, well, if something could
be done to make people more likely to survive trauma […]
so that seems much less likely to be politically contested. I
can imagine a landscape emerging which is different to the
one we currently have. (Ethicist)
Casting genome editing as a contributor to the public good
of better quality of life and health raises considerations of
equity and equality:
[…] in a world where our resources are finite, how much
does it cost to have to put resources here rather than some-
where else? […] we’re talking about it from a genetic point
of view, so once you have the child who’s got this par-
ticular condition and you’re managing […] the child for
12 years […] how many children or other people are suf-
fering and dying because the medication and the healthcare
treatment that’s going there is now not available elsewhere?
(Scientist 1)
Here, genome editing technologies are contextualized in a
world of limited resources, in which the capacity to prevent
genetic disease might enable the resources currently dedicated
to treatment and care of individuals with specific genetic con-
ditions to be redirected toward other healthcare areas and
contribute to more equitable access to treatment. Another
scientist interviewed suggested:
[…] we make value judgements as a society – or somebody
on behalf of society makes value judgements about which
treatment to be given where; and the so-called postcode lot-
tery and this type of issue exist today; and some treatments
are too expensive and some are not. So could this become…
Could this be a way…? […] It’s the distribution; […] it’s
how you get to those individuals, whether it’s 10,000 or
two. How you deliver it to those individuals. (Scientist 2)
Unlike the written reports, some interviewees candidly
contested the linear linkage of research investment now and
health pay-off later, questioning how certain we can be of
the later benefit and what the consequences in terms of
public backlash might be if the promised pay-off does not
materialize:
[…] there is a whole range of other things that we can spend
our money on in the NHS [National Health Service]: the
care for the elderly etc., so, you know, it’s not just about
the ethics of genome editing in the sense of whether it’s safe
or it is acceptable in terms of disability and so on. It’s also
about ‘is this an ethical way to spend money when there are
so many other things we can spend money on?’ (Ethicist)
As they describe the public goods they see genome edit-
ing producing, these opinion makers evoke, and effectively
produce, two broad publics. The first consists of experts
and decision-makers: research scientists, research funders,
regulators, ethicists, clinicians (as potential commissioners
of genome editing), some patient groups, and companies
involved in the production and use of genomic data. The sec-
ond broad public includes potential users or groups likely
to be most directly affected by regulatory decisions, such as
communities with rare genetic diseases and (in)fertility issues
but also wider general publics who might benefit from inter-
ventions that would currently be considered enhancement,
such as making their physiology more resilient to infection
or trauma and more responsive to healing. The current key
public-in-particular, however, consists of patients who par-
ticipate in research or receive treatment:
The most likely relevant publics, at least to begin with, will
be patients. For instance, patients that have taken part in
the 100,000 Genomes Project; or ones who are likely to
have their genome sequenced as the result of the conditions
they have. (Public engagement professional employed by a
major research funder)
Both documents and interviews demonstrate how this pub-
lic is centered in the discourse of genome editing in terms of
the value of developing genome editing technologies as clini-
cal interventions and in terms of their personal experience of
genetic disease.
So these six, seven, eight thousand so-called monogenic
conditions, there are thought to be somewhere in the order
of a million people with one of these conditions in the UK
… Individually, they’re not that common…most of them,
but added together, they add up to something. (Scientist 1)
As discourse identifies publics, it also generates a sense
of solidarity with these enactments of publics-in-particular.
For example, one specifically articulated public contains those
who would like to have genetically related children with sig-
nificantly reduced chances of developing a genetic disease, as
referred to by one interviewee:
Because mum and dad probably would say ‘well we don’t
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so much, but we want to kind of prevent that if we can by
using this method’. (Scientist 1)
Solidarity is also generated for those who are imagined
as wanting to go further, such as those who would like to
enhance their children in medically relevant ways, as a form
of prevention for illnesses that are linked to genetic predis-
position but are not (currently) perceived as genetic (or rare)
diseases:
[…] they’ll say ‘look, we want to have kids’ and their
genome sequences will go up into the cloud, some super-
computer will say: […] Okay, so if you just go ahead
willy-nilly, then there’s a 62% chance that your child will
die of hypertension before they’re 63 years old. … But
then your next door neighbour, they went and did this and
they had something similar, but for coronary heart disease,
and [after editing, the probability] went from 68% […] to
.006%. (Scientist 1)
Wider publics are therefore invoked as part of a promissory
regime that expands the relevance of genome editing to many,
perhaps most members of society, while still anchoring the
present-day discussion in clinical and medical contexts.
8. Discussion: an enabling ethical regime
Both documentary and interview data indicate that the
sociotechnical imaginary of genome editing for human health
posits two key public goods of (1) advancing knowledge about
human biology and (2) raising the quality of life via progress
in healthcare. A promissory ethical regime has developed
that highlights three aspects validating and materializing this
sociotechnical imaginary. The first is a strong focus on acquir-
ing more scientific knowledge, especially in genomics, both
because knowledge or knowledge production is a good in
itself and in order to understand how to apply it effectively.
As a good in itself, knowledge production is made distin-
guishable from the future application of that knowledge. This
distinction effects a discursive separation of the ethical debates
about research—emphasized by adding the term ‘basic’—
from any potential medical applications of such knowledge.
The distinction is also a practical one since the genome editing
technologies likely to have major clinical impact are generally
considered to be still far from implementation: the current
focus is therefore on working with animal models and human
embryos (‘basic research’) to develop the necessary knowledge
base for future use. Both documents and interviews present a
framework in which the ethical route toward development of
genome editing is via the laboratory and of animal models
leading on to clinical trials.55
A second feature of this promissory ethical regime is the
need for transparent and open public debate about genome
editing. However, as evidenced by the key UK reports ana-
lyzed in this paper, the ethical regime itself effectively limits
public debate to confirming the further development and use
of genome editing (both for somatic cells and germline inter-
ventions) rather than opening up discussion of the long-term
aims of human genome editing and the possibility of amorato-
rium. The key participants in this public debate are imagined
to be patient groups, policy makers, and regulators, with
secondary involvement from science funders and academic
researchers. Nonetheless, for some of our interviewees, a
strategic approach to public engagement about genome edit-
ing is still to emerge in part because both public goods and
publics are not yet clearly defined enough:
At the moment [the field] feels too big for us to say, ‘right,
we’re going to have a strategy on how to engage the public
about genome editing,’ because not only is the technol-
ogy so big, but the implications are so broad, and the
affected publics are so wide as well. (Public engagement
professional employed by a major research funder)
The third aspect is the call for legislation to prevent misuse
of the technology. Here, parallels with assisted reproductive
technologies are most frequently invoked, with reference to
‘designer babies’ and other perceived abuses. Several reports
share the view that the existing governance framework in the
UK, in particular, the Human Fertilisation and Embryology
Act 2008 and its executive body the Human Fertilisation and
Embryology Authority (HFEA), is adequate for the research
and development of genome editing technologies. This view
is shared by other bioethicists and commentators who argue,
for example, that ‘We should feel confident that our regula-
tory system in this area [of genome editing] is functioning well
to keep science aligned with social interests.’56 Similarly, the
2016 report by the Genetic Alliance UK proposes an ethical
framework in which
there is an obvious line, already drawn, between the use of
reproductive technology for therapeutic purposes, and the
use of such techniques for human enhancement. […] We
expect this treatment/enhancement distinction will remain
fundamental to the way that technology such as this is
regulated.57
In other words, the ethical distinctions that have structured
the regulation of other technologies are adequate to regulate
genome editing. This confidence is based on arguments of
similarity: technical similarity between genome editing and
existing technologies, such as preimplantation genetic diagno-
sis or mitochondrial replacement therapy, as well as similarity
of aim.58
While this analysis shows how genome editing is cast as
contributing to public goods for publics-in-particular, there
are also many challenges and contestations to doing so,
including whether funds should be spent on developing these
technologies, what kind of value judgements are mobilized,
and what kind of changes can genuinely be considered to be
public rather than mostly private goods. The ethical regime
sketched here is an enabling one: its baseline is that genome
editing is fundamentally in the public interest because of
the public goods it will deliver, if properly regulated, and
therefore any ethical or regulatory framework needs to make
genome editing possible. Such a regime must also articulate
limitations or alternative futures to be avoided to justify the
efforts to bring about the positive future vision. As Richard
Tutton has argued in a study of future-oriented statements
of commercial actors, ‘the co-articulation of pessimistic and
promising futures in such statements constitute an important
site of anticipatory practice’.59
An alternative regime of reproductive skepticism is voiced
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existing modification methodologies because of its capac-
ity to effect heritable changes in assisted reproduction. The
alternative regime of reproductive skepticism is far from dom-
inant in either the expert documents or interviews analyzed
for this paper,60 but it is a powerful element of the wider
public and academic debates. A key feature is a strong dis-
tinction between somatic and germline editing, with only
the former framed as ethically acceptable. In the current set-
ting, an enabling discourse prioritizes proximate goods rather
than potential (and less foreseeable) long-term impacts, while
critical views express concern about the potential for enhance-
ment and the pursuit of longer-term posthumanist ideals. The
enabling approach is further challenged by arguments from
disability studies and disability rights activists that germline
editing makes unjustified value judgements about the quality
of lives lived with certain impairments.61
We identified in the enabling regime a preoccupation with
retaining public trust against any possible future negative
publicity. In a variation on this, the regime of reproduc-
tive skepticism shows concern that any scientific support for
germline editing, which generally is less accepted by the gen-
eral public, will damage the popular perception of science,
referencing other areas of past contestation, such as the early
days of assisted reproduction.
Both the enabling and the skeptical ethical regimes are sim-
ilar in being promissory, proposing rationales for particular
kinds of ethical understanding and regulation, anticipating
which technologies, capacities, needs, and issues may arise,
and proposing governance that indirectly steers how genome
editing should be understood, and which governing parame-
ters should be adopted to shape it. The enabling regime posits
scientific knowledge production now, and improvement of
treatment or prevention of hereditary diseases in the future, as
key public goods of genome editing for human health. Its asso-
ciated key publics are families with hereditary diseases. The
enabling regime is deterministic, considering genome editing
as something that is already applied in research and testing
and so cannot be put back into the box. Interestingly, the
skeptical regime is also built on a notion of technological
inevitability in that it considers that once germline genome
editing has been permitted, its misuse would be inevitable.
It should be emphasized that the technology of genome
editing is far from unique in generating an enabling ethical
regime. Indeed, it fits within a broad sociotechnical imagi-
nary built up over a series of historical precedents in the UK
that, as Dimond and Stephens note, is ‘inherently amenable’
to technological implementation.62 However, each technol-
ogy is distinctive and exists in a particular social and political
context, and its associated enabling ethical regime is similarly
distinctive.
A comparison with the debate over developing mitochon-
drial replacement technology (MRT) is particularly instructive
in highlighting the public goods and publics identified com-
pared to the case of genome editing. The major public good
evoked in the MRT discussion was the possibility of rapid
progress toward the clinical benefit of intervening to pre-
vent the transmission of mitochondrial disease. This contrasts
strongly with our analysis of genome editing discourse, where
most documents and interviewees prioritize the acquisition
of knowledge and insist that it is separable from far-distant
application. In line with this, the primary public-in-particular
benefitting fromMRTwas the small number of families at risk
of mitochondrial disease, and their children. What is particu-
larly interesting here is that, until the discussion of legislative
change began in the early 2000s, mitochondrial disease was
virtually unknown to non-specialists, unlike the broad notion
of ‘genetic disease’, which is much more familiar to the gen-
eral public. Unlike the public constituted by genetic disease,
then, the public-in-particular of those affected by mitochon-
drial disease was effectively brought into being by the ethical
debate and inserted into the sociotechnical imaginary over a
very short space of time. In the various reports and recom-
mendations about mitochondrial research and the law that
appeared between roughly 1998 and 2016,63,64 virtually no
use was made of arguments about the good of knowledge in
itself, of the benefit to researchers outside the area of mito-
chondrial disease, or of the other potential beneficiaries of
MRT, such as older infertile women or same-sex couples
wanting to have genetically related offspring. Perhaps, the
radical and controversial step of permitting a (contested) form
of genetic manipulation, previously forbidden under UK law,
required a focus on a rapidly achievable clinical benefit that
could be carefully restricted to a numerically small, vulnerable
group and the potential for more extensive use to be down-
played.65 This is in stark contrast to the enabling discourse
of genome editing described in this paper. Another contrast
with genome editing is that expert discussion of MRT pre-
sented the chance for families with mitochondrial disease to
have genetically related children as a central good delivered
to this restricted population. In the discourse of genome edit-
ing, the good of genetic relatedness, although important, is
not nearly so central.
9. Conclusion
This analysis has built on the understanding that reasoning
about an emerging field of technology is anticipatory and that
ethical considerations are an integral aspect of sociotechnical
imaginaries. The promissory expectations of genome editing
become manifest in actual and discursive infrastructure build-
ing, such as the establishment of various scientific and social
scientific oversight groups to deliberate genome editing—
sometimes involving self-identification by the commissioners
or authors. In a promissory context, ethical regimes antici-
pate the moral futures of a specific concern or material—in
this case, the human genome—and also of emerging tech-
nologies that engage with such concerns and materials. The
articulation of publics and public goods becomes part of the
attempt to frame and structure an emerging field. By associat-
ing specific publics and public goods with values and norms,
the promissory ethical regime prescribes a role for the tech-
nology in the trajectory toward a specific desirable future.
These publics and goods then provide ethical rationales for the
suggested promissory (i.e. future) governance of the emerging
field of research.
The ‘expert’ UK discussion of genome editing for human
health, including its regulatory dimension, has therefore pro-
duced a generally enabling climate, with a focus on scientific
research to improve the understanding of the technology in
order to advance toward clinical treatment and prevention
of genetic diseases. However, our analysis suggests that the
UK’s enabling promissory ethical regime for genome editing
calls into being the relevant publics-in-particular rather than
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that includes representation from more, and more varied,
public interest groupsmight reflect different norms about pub-
lic goods than the ‘expert’ sociotechnical imaginary we have
explored here. The Nuffield Council on Bioethics, for exam-
ple, has strongly advocated a broader and more inclusive
public engagement that goes beyond the current emphasis on
professional and academic inputs. Greater differentiation of
potential users of genome editing may be necessary to break
away from subsuming all either as research participants or
under a generic notion of patient. A further distributed delib-
erative governance approach to public debate can reflect on
what might be hidden assumptions about goods and publics,
as well as make visible previously invisible, or ignored, publics
and public goods. Bringing those assumptions to light in a
broader and more inclusive debate might help ensure that
science/research/innovation policy is ‘enabling’ without being
‘deterministic’.
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Notes
1. Nuffield Council on Bioethics (2016: 4, 12).
2. E.g. Jinek et al. (2012).
3. For a review of the concept of ‘disruptive technology’, see e.g.
Danneels (2004).
4. The Academy of Medical Sciences et al. (2015).
5. See, for example, the Royal Society’s 2016 animated video
‘What is gene editing and how does it work?’, available at
https://youtu.be/XPDb8tqgfjY (accessed on 4 June 2018).
6. Jasanoff and Kim (2009: 123).
7. Pickersgill (2011).
8. Barben et al. (2008).
9. Selin (2011).
10. Callon (1999).
11. Marris and Calvert (2020).
12. Radin and Kowal (2015).
13. Stephens et al. (2013).
14. Warner (2002: 50).
15. Engdahl and Lidskog (2014).
16. Haerlin and Parr (1999).
17. Wynne (2006).




22. Rommetveit and Wynne (2017: 143).
23. In our understanding of the UK’s specific landscape of expertise
around bioethical issues, we draw fromAshcroft (2004), Chadwick
and Wilson (2018), Chan (2015), Hedgecoe (2009), and Jasanoff
(2005).
24. Gunnarsdottir and Rommetveit (2017).
25. Callon (1994).
26. Schmid et al. (2012: 54).
27. Reubi (2012).





32. The Academy of Medical Sciences et al. (2015).
33. The Hinxton Group represents an international, multidisciplinary
consortium of scholars from social sciences, humanities, and sci-
ences. The group is led by a committee of scientists and bioethi-
cists, including Sarah Chan, Ruth Faden, John Harris, and Julian
Savulescu, whose work on ethical and policy aspects of biotech-
nologies, for example, for human embryo and stem cell research,





37. Sciencewise is a UK Government-funded body, developing pub-
lic dialogue projects with diverse British publics on topics
that are related to Government-identified strategic priorities:
https://sciencewise.org.uk/.
38. Sciencewise and Nuffield Council on Bioethics (2016).
39. Parliamentary Office of Science and Technology (2016).
40. Church of England (2016).
41. Genetic Alliance UK (2016).
42. The Chief Medical Officer (2017).
43. House of Commons Science and Technology Committee (2017).
44. Genetic Alliance UK and Progress Education Trust (2017).
45. The 2016 platform report produced by the Nuffield Council on
Bioethics is included, but the 2018 report on human reproduction
and genome editing is not since it was published after the analysis
was completed.
46. Nature Methods Editorial (2012).
47. However difficult it may be to uphold the distinction between basic
and translational in genome editing (Nuffield Council on Bioethics
2016: 40).
48. Concerns that seem to have been proven correct on the later
examples of Chinese researchers editing genes in human embryos
since 2015, cf. Cyranoski (2019); and researchers from the USA
conducting mitochondrial replacement in Mexico in 2016, cf.
Palacios-González and Medina-Arellano (2017).
49. In addition to the reports and scientists referenced here, see also
Chneiweiss et al. (2017).
50. Jesse Gelsinger was a young man who died during a clinical trial
of a gene therapy at the University of Pennsylvania in 1999. Sub-
sequent inquiries indicated severe flaws in the informed consent
process of the trial.
51. Genetic Alliance UK (2016: 34).
52. The Hinxton Group (2015).
53. The Academy of Medical Sciences et al. (2015).
54. Nuffield Council on Bioethics (2016).
55. Note, however, that a distinction is made between somatic and
germline editing in terms of research and application.
56. Bioethicist Dr Sarah Chan, Gallagher (2016).
57. Genetic Alliance UK (2016).
58. In practice, the current ethical regime and its governance
structure does leave space for future legislation once appli-
cations using CRISPR variants become available for clinical
application.
59. Tutton (2011: 425).
60. These sources, especially the documents, focus on proximate goods
closely linked to health-related research outcomes. While longer-
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the dimension critical of genome editing tends to be associated with
the human enhancement narrative, which is often framed as a less
realistic concern in the current debate.
61. Of course other selective technologies do the same, but the cri-
tique here highlights the potentially irreversible nature of germline
genome editing.
62. Dimond and Stephens (2018b: 133).
63. Craven et al. (2016).
64. Appleby (2015).
65. Dimond and Stephens (2018a).
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